Bristol-Myers Squibb Company · NYSE:BMY
Bristol-Myers Squibb — Investor Presentation (April 2019)
136 slides from Bristol-Myers Squibb's investor presentation, April 2019
Slide 1: CT Lung Screening: Moving the Needle Forward
CT Lung Screening: Moving the Needle Forward Andrea McKee, MD Department of Radiation Oncology Lahey Hospital & Medical Center Burlington, MA April 2019 1 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 2: Disclosures
Disclosures • Covidien speaking honoraria 2 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 3: Outline
Outline • Screening the high risk population- organizational change • Population health • Screening beyond USPSTF 3 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 4: In the beginning…
In the beginning… 1600s Tobacco Ad 4 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 5: Cigarette Rolling Machine 1880
Cigarette Rolling Machine 1880 • James Albert Bonsack (age 21 years) • Result of a contest (prize $75K) to invent machine to roll cigarettes. • 120,000 cigs in 10 hours (200/min) • Revolutionized industry 5 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 6: Rise and Fall of Smoking
Rise and Fall of Smoking $119 out of $205 billion 7 million deaths per year worldwide 179 billion in US healthcare costs 150 billion in lost US productivity 6 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 7: The future is… JUUL
The future is… JUUL Adam Bowen James Monsees > 60% mkt share JUUL on TWITTER 1 pod= 60mg Nicotine 1cig=9mg and 1mg after burning 7 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 8: Primary Prevention: Risk Factor Modification
Primary Prevention Risk Factor Modification • Tobacco Smoke (~90%) – Start age, Duration, Quantity, Type of cigarette – > 20x increased risk of lung cancer 8 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 9: Primary Prevention: Smoking Cessation
Primary Prevention Smoking Cessation • Ancillary Benefits – Decreases morbidity of the many other smoking related disease processes – ~ 1/2 of regular smokers die from smoking related disease (~30% lung cancer) 9 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 10: Race and Lung cancer
Race and Lung cancer White male smokers consume 30%–40% more cigarettes than their black counterparts, but black male smokers are 34% more likely to develop lung cancer. Black women smoke less on average than white women but have similar incidence rates 10 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 11: African Americans have the highest incidence of and mortality from lung cancer
African Americans have the highest incidence of and mortality from lung cancer 11 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 12: 12 RESCUE LUNG RESCUE LIFE SOCIETY
12 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 13: 5 A's US Public Health Service Provider Role
5 A’s US Public Health Service Provider Role Ask Identify tobacco use Documented Advise Clear, strong, personalized Reasons to quit Assess Willingness Readiness determined Assist Counseling/pharmacotherapy Strategies explained Arrange Schedule follow up Purpose directed follow up Clinical Practice G
Slide 14: Opportunities for Smoking Cessation
Opportunities for Smoking Cessation (Over two screening rounds) SDM Meeting/ Baseline Order •PCP (4) Baseline Satisfaction incidence 11 Order exam •Navigator (5) chances •CT Tech (2) Discuss Scheduling Incidence Eligibility incidence Satisfaction Confirmation Baseline Results exam Assessment 30% Tel
Slide 15: Results: Relapse Rates vs General Population
Results Relapse Rates vs General Population Quit < 1 year Quit > 1 year Garcia-Rodriguez O, Secades-Villa R, Florez-Salamance L, Okuda M, Liu S-M, Blanco C. Probability and predictors of relapse to smoking: Results of the epidemiological survey on alcohol and related conditions (NESARC). Drug and Al
Slide 16: NCI Smoking Cessation at Lung Examination Collaboration (SCALE)
NCI SMOKING CESSATION AT LUNG EXAMINATION COLLABORATION (SCALE) LUNA Integrated care vs quitline vs quitline plus MATCH CER digital cessation alone, in combo with counselor or refer to care PLUTO SMART design telephone vs telephone plus pharm (monthly vs quarterly contact) CASTL Motivational intervi
Slide 17: Secondary Prevention: CT Lung Screening
Secondary Prevention CT Lung Screening • Most people who die from lung cancer now are FORMER SMOKERS – 35% of Lung Cancer Diagnosis à Current Smokers – 50% of Lung Cancer Diagnosis à Former Smokers – 15% of Lung Cancer Diagnosis à Never Smokers • Lung Cancer 5-Year Overall Survival – 1975 5yrOS à 12
Slide 18: Current Former
Current Former 18 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 19: RESCUE LUNG RESCUE LIFE SOCIETY
19 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 20: Why so slow?
Why so slow? Reimbursement Silos Stigma Misinformation Terminology Infrastructure Resources Training 20 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 21: Screening uptake after recommendation and coverage
2016 data, 3 years after ACS recommendation and one year after CMS coverage Mammography -28% in 1987, 11 years after ACS recommendation Colonoscopy -32% in 1980, 20 years after ACS recommendation Lung cancer screening Lahey– 65% in 2018, 6 years after NCCN recommendation 65% of eligible population s
Slide 22: Kotter's Organizational Change
Kotter’s Organizational Change ACCC Oncology Times March /April 2014 22 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 23: Lung Screening Urgent Need
Lung Screening Urgent Need Lung Cancer Claims the lives of 450 People Every Day 23 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 24: Access to Life-Saving Intervention
Access to Life-Saving Intervention 24
Slide 25: Powerful Coalition
Powerful Coalition ACCC Oncology Times March/April 2014 25 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 26: Create Vision: Rescue Lung, Rescue Life
Create Vision Rescue Lung, Rescue Life Mission v Save lives through the early detection of lung cancer with responsible CT lung screening v Encourage the government to establish reimbursement for CT lung screening v Encourage other centers of excellence in the treatment of lung cancer to offer respo
Slide 27: cam GV tue ys
ae cam GV tue ys LOVERS* Bivue ~ » DESERVE DESERVS.. TO DIE TO DIE
Slide 28: No One Deserves to Die of Lung Cancer
No One Deserves to Die of Lung Cancer 28 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 29: Stigma and Big Tobacco
Stigma and Big Tobacco Competition has been tough - tobacco industry, Hollywood, press Guard against withholding of health care services or advocacy based on social history – slippery slope 29 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 30: Revenues and Expenses: Different Silos
Revenues and Expenses Different Silos Pathology CT Surgery Oncology Cardiology Pulmonary Internal Med Radiology 30 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 31: Financial Analysis Year 2 (2nd Incidence)
Financial Analysis Year 2 (2nd Incidence) Total Revenue to Radiology à $257,115 Total Cost to Radiology à $187,894 Net Gain/Loss to Radiology à GAIN ~$70,000 31 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 32: Lives Saved/Net Revenue
Lives Saved/Net Revenue Lives Saved/Net Revenue • 1 years and 3 years • Mkt Share 32 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 33: Clinical Resource Utilization
Clinical Resource Utilization • 711 clinical CT lung screening pts. • Followed for 12 months after screening • Chart review • Include all clinical activity with > 95% chance of being directly result to lung screening event • Breakdown volume by hospital departments and Lung-RADS score 33 RESCUE LUNG
Slide 34: Overall Financial Events 12 Months: 711 Patients
Overall Financial Events 12 Months: 711 Patients 1,420 34 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 35: Hospital Events (12 months: 711 Patients)
Hospital Events (12 months: 711 Patients) 35 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 36: Model Projections vs Clinical Observations
Model Projections vs Clinical Observations 36 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 37: Kotter's Organizational Change
Kotter’s Organizational Change ACCC Oncology Times March/April 2014 37 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 38: LungRADS
LungRADS ACCC Oncology Times March/April 2014 38 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 39: CMS Payment Drives Adoption and Access
CMS Payment Drives Adoption and Access 11/13/12 Meet with CMS 12/28/2011 USPSTF NCCN (12/2013) 11/8/2010 10/26/2011 CME CMS(2/2015) NLST trial halted; Screening is 12/15/2011 Campaign Open access; low-dose CT recommended for scans reduce lung LungRADS 9 million at risk high-risk individuals Only 2-3
Slide 40: RESCUE LUNG RESCUE LIFE SOCIETY
40 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 41: Request coverage, demonstrate LungRADS, message relentlessly
1. Request coverage 2. Demonstrate LungRADS system 3. Message relentlessness 41 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 42: RESCUE LUNG RESCUE LIFE SOCIETY
42 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 43: lungcancerscreeningguide.org
https://www.lungcancerscreeningguide.org 43
Slide 44: Screen
Screen NCCN 44 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 45: Training Credentialed Radiologists
Training Credentialed Radiologists Radiology- Make the radiologist comfortable Mevis Lung Academy IELCAP VA PALS NELSON: Central Radiology Review Pulmonary Recommendation for suspicious European 18 month implementation plan 45 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 46: Systems Approach
Systems Approach Division of labor cost efficient/effective volume for PCP, specialist, radiology Triage to manage specialty volume 46 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 47: RESCUE LUNG RESCUE LIFE SOCIETY
47 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 48: Lung Screening Debate: Fact vs Speculation
Lung Screening Debate Fact vs Speculation NCCN Considerations Proven Risks/Benefits Theoretical Risks/Benefits v At least a 20% lung cancer v Increase/decrease pt. anxiety specific mortality benefit v Encourage/discourage v False positive rate smoking v False negatives v Patients to ignore symptoms
Slide 49: RESCUE LUNG RESCUE LIFE SOCIETY
49 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 50: MILD and Landmark mortality analysis
MILD = 65% Men 10 Yr LC Specific Mortality = 39% Landmark = 58% 50 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 51: Eligibility NELSON, MILD, NLST
Eligibility NELSON, MILD, NLST • NELSON • NLST • Age: 50-75 • Age: 55-74 • Current or quit < 10 yrs ago • Current or quit < 15 yrs ago • > 10 cig/day x 30 yrs (15PY) • > 30 Pack Years (PY) • > 15 cig/day x 25 yrs (18.75 PY) • MILD • Age 49-75 • Current or quit < 10 yrs ago • ≥20 pack years (PY) 51 R
Slide 52: NELSON and MILD - Demographics
NELSON and MILD- Demographics Lahey 65 58 Lahey Mild Mild 38 Lahey Lahey Lahey Mild 52 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 53: NELSON
NELSON • ~16,000 randomized CT vs no screening • 4 exams over 5.5 years evaluate at year 10 – Baseline, year 1, year 3, year 5.5 • Volumetric imaging • Central reading • Pulmonary referral suspicious • 16% women 53 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 54: MILD
MILD • 4099 randomized CT vs no screening (2 to 1) • 5 year results NS difference • 10 year Landmark analysis to assess efficacy of long term screening 54
Slide 55: MILD participant characteristics
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. MILD Characteristics of the 4,099 participants in the MILD population, by study arm. Control arm Intervention arm P-values (N= 1,723) (N = 2,376) Age (years) <55 656 (38.1%) 773 (32.5%)
Slide 56: Significance for US Screening?
Significance for US Screening? • USPSTF review underway • Category A recommendation • CMS Implications – SDM – Registry 56 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 57: Shared Decision Making
Shared Decision Making Editorials Exaggerating Radiation Harm and FPR What is the false positive rate in modern clinical practice CTLS? 98%, 60%, 50%, 23%, 12%, 7%, 2% Patient Anxiety – Little/No Evidence “Permission to Smoke” – Little/No Evidence Overdiagnosis What is the rate of overdiagnosis in t
Slide 58: What is the False Positive Rate? What is NOT the False Positive Rate?
What is the False Positive Rate? “On a population-based level, the FP rate is traditionally defined as the probability of receiving a positive result, given an absence of the disease. In this review, the FP rate will be defined as the number of FPs as a proportion of the total number of screening ex
Slide 59: False positive rate vs false discovery rate formulas
• False positive rate = B / (D + B) • False discovery rate = B / (A + B) 10/1000000 = .001% = FPR 10/11= 90% = FDR 59 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 60: False Positive Rate vs False Discovery Rate
False Positive Rate vs False Discovery Rate Test # Screened Positive True Positive False FPR FDR Exams Negative A 106 100 10 1 ? ? B 500 100 10 1 ? ? C 1,000 100 10 1 ? ? D 10,000 100 10 1 ? ? E 100,000 100 10 1 ? ? F 1,000,000 100 10 1 ? ? 60 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 61: False Positive Rate vs False Discovery Rate
False Positive Rate vs False Discovery Rate Test # Screened Positive True Positive False FPR FDR Exams Negative A 106 100 10 1 95% ? B 500 100 10 1 18% ? C 1,000 100 10 1 9% ? D 10,000 100 10 1 0.9% ? E 100,000 100 10 1 0.09% ? F 1,000,000 100 10 2 0.009% ? 61 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 62: False Positive Rate vs False Discovery Rate
False Positive Rate vs False Discovery Rate Test # Screened Positive True Positive False FPR FDR Exams Negative A 106 100 10 1 95% 90% B 500 100 10 1 18% 90% C 1,000 100 10 1 9% 90% D 10,000 100 10 1 0.9% 90% E 100,000 100 10 1 0.09% 90% F 1,000,000 100 10 1 0.009% 90% 62 RESCUE LUNG RESCUE LIFE SOC
Slide 63: False Positive Rate vs False Discovery Rate
False Positive Rate vs False Discovery Rate Test # Screened Positive True False Sensitivity Specificity FPR FDR Exams Positive Negative A 106 100 10 1 91% 5% 95% 90% B 500 100 10 1 91% 82% 18% 90% C 1,000 100 10 1 91% 91% 9% 90% D 10,000 100 10 1 91% 99% 0.9% 90% E 100,000 100 10 1 91% ~100% 0.09% 9
Slide 64: False Positive Rate vs False Discovery Rate
False Positive Rate vs False Discovery Rate Test # Screened Positive True False Sensitivity Specificity FPR FDR Exams Positive Negative A 106 100 10 1 91% 5% 95% 90% B 500 100 10 1 91% 82% 18% 90% C 1,000 100 10 1 91% 91% 9% 90% D 10,000 100 10 1 91% 99% 0.9% 90% E 100,000 100 10 1 91% ~100% 0.09% 9
Slide 65: False Positive Rate vs False Discovery Rate
False Positive Rate vs False Discovery Rate False Positive Rate False Discovery Rate Screening NLST NLST LR LHMC MG NLST NLST LR LHMC MG Round T0 26.3% 12.6% 10.6% ~20% 96.2% 92.8% 83.1% 97% T1 27.2% 5.3% 5.2% 5-10% 97.6% 90.3% 78.2% 95% T2 15.9% 5.1% 5.0% 5-10% 94.8% 87.2% 84.6% 95% Actual Lung Scr
Slide 66: False Positive Rate vs False Discovery Rate
False Positive Rate vs False Discovery Rate False Positive Rate False Discovery Rate Screening NLST NLST LR LHMC MG NLST NLST LR LHMC MG Round T0 26.3% 12.6% 10.6% ~20% 96.2% 92.8% 83.1% 97% T1 27.2% 5.3% 5.2% 5-10% 97.6% 90.3% 78.2% 95% T2 15.9% 5.1% 5.0% 5-10% 94.8% 87.2% 84.6% 95% Actual Lung Scr
Slide 67: False Positive Rate vs False Discovery Rate
False Positive Rate vs False Discovery Rate False Positive Rate False Discovery Rate Screening NLST NLST LR LHMC MG NLST NLST LR LHMC MG Round T0 26.3% 12.6% 10.6% ~20% 96.2% 92.8% 83.1% 97% T1 27.2% 5.3% 5.2% 5-10% 97.6% 90.3% 78.2% 95% T2 15.9% 5.1% 5.0% 5-10% 94.8% 87.2% 84.6% 95% Actual Lung Scr
Slide 68: What ARE the False Positive Rates for CT Lung Screening?
What ARE the False Positive Rates for CT Lung Screening? T0: 26.3% T1: 27.2% T2: 15.9% Overall: 23.3% T0: 12.6% T1: 5.3% T2: 5.1% Overall: 7.8% T0: 10.6% T1: 5.2% T2: 5.0% Overall: 7.6% Rescuing lives from lung cancer today and tomorrow 68 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 69: Quote on NLST false positive rate of 96.4%
“With the results of the American study National Lung ScreeningTrial (NLST), published in 2011, for the first time a lung cancer-specific mortality reduction by 20% thanks to the use of LDCT compared to RXT, was highlighted. However, a false positive rate of 96.4% was also described with an overdiag
Slide 70: Quote on NLST positive screening tests
“Overall, 39.1% of participants in the NLST LDCT group had at least one positive screening test, with a false positive rate of 96.4% across the three rounds of screening.” Rescuing lives from lung cancer today and tomorrow 70 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 71: Quote on LDCT mortality reduction and false positivity
“Objective and Rationale: Lung cancer screening with low-dose CT (LDCT) has been shown to reduce mortality by 20%, although there are concerns including high false positivity, cost, and radiation exposure. Of note, the false positive rate of lung cancer screening with LDCT alone was 96.4% in the Nat
Slide 72: Quote on NLST critique and patient anxiety
“Perhaps one of the most commonly cited critiques of the NLST is the high false-positive rate (96.4%), which led to further diagnostic tests and unnecessary invasive procedures. While some have suggested that this contributes to patient anxiety and worsening quality of life (QOL), a formal analysis
Slide 73: Rescuing lives from lung cancer today and tomorrow
Rescuing lives from lung cancer today and tomorrow 73 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 74: 2106 patients screened; 1257 positive exams; 31 confirmed lung cancers
Ø 2106 patients screened; 1257 positive* exams; 31 confirmed lung cancers Ø False positive* rate = (1257 – 31) / 2106 = 58.2% Ø False suspicious rate = (73 – 31) / 2106 = 2% “There was wide variation among sites in the percentage of screening test results that were positive for nodules or possible l
Slide 75: Jan 2017 JAMA Internal Medicine Article
Jan 2017 JAMA Internal Medicine Article “The rate of false-positive test results for lung cancer was 97.5% (1226 of 1257) during the 330-day follow-up period” “The reason for the overall high rate of initially positive examination results in the VHA sites is not certain but may be owing, in part, to
Slide 76: Quote on 2106 screened patients and nodules
“Of the 2106 screened patients, 1257 (59.7%) had nodules, and 1184 (56.2%) required tracking. Only 42 (2.0%) patients required further evaluations that did not result in a lung cancer diagnosis, and only 31 (1.5%) were diagnosed with lung cancer within 330 days. Overall, researchers calculated a fal
Slide 77: Quote on JAMA studies of lung screening implementation
“A pair of studies in JAMA Internal Medicine illustrate the difficulties of implementing lung cancer screening. In the first, eight Veterans Health Administration medical centers identified and screened patients using low-dose computed tomography (LDCT). Over 2100 patients who were eligible for scre
Slide 78: Aug 2018 JAMA Internal Medicine Shared Decision Making article
Aug 2018 JAMA Internal Medicine Shared Decision Making article “We identified 5385 conversations involving age-eligible patients occurring between April 1, 2014, and March 1, 2018. Of these, 137 met the key word criteria. Manual review of these transcripts yielded 14 conversations about initiation o
Slide 79: Aug 2018 JAMA Internal Medicine article
Aug 2018 JAMA Internal Medicine article “No physician adequately explained false positives or their sequelae. No physician discussed overdiagnosis”. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2696731 79 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 80: Quote on discussions lacking harms mention
“Even in the highest-rated discussions, there was no mention of possible harms from the screening by the physicians, even though these harms include a 98% false-positive rate, which may lead to anxiety; additional testing including imaging or procedures, such as biopsy or lobectomy; and radiation fr
Slide 81: SDM comments
SDM 2 Comments for this article COLLAPSE August 13, 2018 Appalling Anthony Glaser, MD, PhD | Paladina Health Hard to believe that "Even in the highest-rated discussions, there was no mention of possible harms from the screening by the physicians, even though these harms include a 98% false-positive
Slide 82: 671 patients screened; 132 positive exams; 16 confirmed lung cancers
• Baseline LDCTS were performed in 671 patients • The number of patients with Lung-RADS scores of 1, 2, 3, and 4 were 306 (45.6%), 233 (34.7%), 76 (11.3%), and 56 (8.3%), respectively • Therefore, a positive test with a score of 3 or 4 was obtained in 132 patients (19.7%) screened at baseline • Ulti
Slide 83: Rescuing lives from lung cancer today and tomorrow
Rescuing lives from lung cancer today and tomorrow 83 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 84: These are all false discovery rates
D E F G H I D: 95.5% = 106 / 111 ≠ false positive rate E: 94.6% = (259 – 14) / 259 ≠ false positive rate F: 94.1% = 1773 / 1883 ≠ false positive rate G: 93% = (114 – 8) / 114 ≠ false positive rate H: 92.6% = (298 – 22) / 298 ≠ false positive rate I: 92.1% = (279 – 22) / 279 ≠ false positive rate THE
Slide 85: Is This Misrepresentation Happening for All Cancer Screening?
Is This Misrepresentation Happening for All Cancer Screening? Not using false discovery rate when discussing ovarian cancer screening Rescuing lives from lung cancer today and tomorrow 85 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 86: Radiation Exposure
Radiation Exposure Years of annual LDCT <1 mSv lung screening Mammogram .7 mSv Lumbar Spine Films 2 mSv 2 Diagnostic Chest CT 10 mSv 10 Triphasic CT AB/P 25 mSv 25 Background 3 mSv/year 3 Exposure Colorado 4.5 mSv/year 4.5 Occupational 50 mSv/year 50 Exposure Transatlantic Flight .1 mSv 7 flights =
Slide 87: RESCUE LUNG RESCUE LIFE SOCIETY
87 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 88: Example patient radiation dose
Lahey CTLS exams 1/1/2016 – 12/31/2017 Example patient: • DLP = 46.45 mGy-cm • Group 2 • E = DLP * k • In program for all years eligible • E = 46.45 * 0.014 (age 50-80; 30 years) • E = 0.65 mSv • THREE screening exams a year • 58.5 mSv Radiation workers – 50mSV per year 88 RESCUE LUNG RESCUE LIFE SO
Slide 89: Future Dose Reduction Opportunities
Future Dose Reduction Opportunities • With continued advances in technology the IR time will continue to approach, possibly drop below, that of FBP • CT Lung Screening with Second Generation IR nearing dose of CXR 89
Slide 90: Significant Incidental Findings
Significant Incidental Findings 90 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 91: Quality Metrics - Agreement on Terminology
Quality Metrics - Agreement on Terminology 91 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 92: Secondary Prevention Preclinical Diagnosis
Secondary Prevention Preclinical Diagnosis Asymptomatic 58% 5-year OS Symptomatic Screening Stage I Stage IV 88% 10-year OS 1% 5-year OS 92 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 93: Secondary Prevention Preclinical Diagnosis
Secondary Prevention Preclinical Diagnosis 58% 5-year OS Asymptomatic Stage I 88% 10-year OS October 26, 2006 N Engl J Med 2006; 355:1763-1771 DOI: 10.1056/NEJMoa060476 93 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 94: Overdiagnosis, Survival, Mortality
Overdiagnosis, Survival, Mortality Survival Diagnosis Death 94 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 95: Overdiagnosis, Survival, Mortality
Overdiagnosis, Survival, Mortality Survival Mortality Diagnosis Death 95 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 96: Lung Cancer Mortality
Lung Cancer Mortality Survival Mortality 365 Death due to lung cancer = 20% 443 Diagnosis Death 96 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 97: Overall Mortality
Overall Mortality Survival Mortality 1877 Death due to any cause across entire group= 6.6% 2000 Diagnosis Death 97 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 98: Overdiagnosis
Overdiagnosis Determine time and cause of death in those patients diagnosed and treated for lung cancer Mortality Patz overdiagnosis NLST excluding BAC 3% Diagnosis Death 98 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 99: Methods
Methods Adenocarcinomas CTLS 70 Tumors High Smoke Low Smoke/No smoke 98 54 Tumors Tumors Pathologic Stage I AIS pT1a/b pT2a 99 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 100: Comparison of Clinical Features of Patients with 208 Stage I Adenocarcinomas
Table 1: Comparison of Clinical Features of 202 Patients with 208 Stage | ie) Adenocarcinomas HS CTLS LSINS lig Patients/Resections/Tumors n=86/89/98__n=63/65/70__n=53/54/54 value Age [median (Q1-Q3)] 68 (62-71) 66(60-72) 67 (62-76) 0410 Gender 0.014 Male (%) 43 (50) 31 (49) 14 (26) Female (%) 43 (5
Slide 101: Systematic Histologic Evaluation in 5% Increments
Systematic Histologic Evaluation in 5% Increments •Minimally Invasive •Colloid Adenocarcinoma •Invasive Mucinous •Lepidic Predominant •Large Cell •Acinar Predominant •Pleomorphic Carcinoma •Papillary Predominant •Cribriform Carcinoma •Solid Predominant •Micropapillary Predominant Mitotic grade, Visc
Slide 102: Low smoke/No smoke vs CTLS invasion rates
Low smoke/No smoke – 22% ALI and 4% VPI VS CTLS 44% ALI and 22% VPI 102 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 103: Exome RNA sequencing
Exome RNA sequencing Overtly Malignant Potential 75-80% for CTLS and HS groups vs 56% for LS/NS 103 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 104: Pathologic Comparison of Prevalent vs. Incident CT Lung Screen Detected Cancer
Pathologic Comparison of Prevalent vs. Incident CT Lung Screen a Detected Cancer in NCCN High-Risk Subjects: Are They Different? Rescue —) Burks, JM Sands, TB Sullivan, SM Regis, B] McKee, AB McKee, KM Rieger-Christ Lahey Hospital & Medical Center, Burlington, MA Py Background CT lung cancer screeni
Slide 105: Cost per life-year saved
An Actuarial Analysis Shows That Offering Lung Cancer Screening As An Insurance Benefit Would Save Lives At Relatively Low Cost • Cost per life-year saved would be below $19,000 Pyenson et al, Health Affairs 31, No.4 770- 779: April 2012 105 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 106: Measure All LCSR
Measure All LCSR Num-Den 976 177466 177466 94.16 (919/976) 90.69 (160946 / 177466 ) Smoking cessation counselling offered (%) 100.00 (976/976) 78.03 (138476 / 177466 ) Smoking cessation counselling offered among current smokers (%) 100.00 (500/500) 85.44 (89260/ 104472) Radiation exposure 1 Mean CTD
Slide 107: What's in the Box?
What’s in the Box? Reimbursement = Access to Screening Reimbursement Access 107 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 108: Who's in The Box? NLST
Who’s in The Box? Lung Cancer Risk Factors •Personal Cancer History •Family History Lung Ca NLST •Carcinogen Exposure ü Age •Chronic Lung Disease •Sex ü Smoking History •Race •Education •BMI Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screeni
Slide 109: NCCN Guidelines: High-Risk Groups
NCCN Guidelines®: High-Risk Groups Group 1 Group 2 (Category 1 Recommendation) (Category 2A Recommendation) 55–74 years old > 50 years old Are currently a smoker or have Have smoked at least a pack of quit within the past 15 years cigarettes a day for 20+ years Have one additional lung cancer Have s
Slide 110: NCCN Model Based Risk
NCCN Model Based Risk Group 1 vs Group 2 6 Year Risk of Developing Lung Cancer (PLCOm2012 Tammemagi) Group 1: 65y, 30 PY, Current 2.5% Group 2: 65y, 25 PY, Current, +Fam Hx 3.8% Group 1: 56y, 40PY, Current 1.5% Group 2: 53y, 40PY, Current, +Fam Hx 2.1% Group 1: 65y, 30PY, Quit x 6y 1.6% Group 2: 65y
Slide 111: OOTB: >30 PY & >15 Quit Years
OOTB: > 30 PY & > 15 Quit Years Current Smokers Quit age 60-64 Quit age 55-59 Never Smokers (Halpern, et al. JNCI 1993;85(6) Quitting after age 50 reduces the risk of lung cancer death compared with current smokers, but following a plateau after cessation, risk of lung cancer death rises significant
Slide 112: OOTB: >30 PY & >15 Quit Years
OOTB: > 30 PY & > 15 Quit Years PLCO Pinsky PF, Zhu CS, Kramer BS. Lung cancer risk by years since quitting in 30+ pack year smokers. Journal of medical screening. 2015;22(3):151-157. Tammemagi MC, Church TR, Hocking WG, Silvestri GA, Kvale PA, et al. (2014) Evaluation of the Lung Cancer Risks at Wh
Slide 113: OOTB: >30 PY & >15 Quit Years
OOTB: > 30 PY & > 15 Quit Years • Gradual decrease with years since quit – No dramatic drop-off after 15 years – Substantial elevated risk vs never smokers even at 30 years since quit. • Cigarettes per day higher in 30PY former smokers than current smokers. • Histology of lung cancer in Over 15 QY m
Slide 114: Lung Cancer Survivors
Lung Cancer Survivors • AATS: Annual surveillance for life – Patient must have ability to undergo curative therapy • Group excluded from randomized trials • 3% risk of lung cancer diagnosis each year – 13-20% develop other second primary lung tumor or other aerodigestive tumor at 6-8 years post ther
Slide 115: Out of the Box
Out of the Box AATS Recommendation • USPSTF & no QY limit • >50, >20 PY, >5% risk of lung cancer in 5 years. • Lung Cancer Survivors Jaklitsch MT, Jacobson FL, Austin JH, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scan
Slide 116: Forget the Box?
Forget the Box? Community Benefit Screening ØCompliance Approval ØNo reimbursement Reimbursement ØNo advertisement ØAll or nothing Good Luck! 116 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 117: Population Health
Population Health • Smoking Cessation • Coronary artery calcifications • Emphysema/COPD • Quantitative Imaging 117 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 118: Applications of Imaging - Airway Disease
Quantitative Computer Tomography Applications Applications of Imaging -Airway Disease -Parenchymal Disease -Vascular Disease -Extra-Pulmonary Atlas of COPD, Springer Science. 2008 118
Slide 119: Coronary Artery Calcifications
Coronary Artery Calcifications 119 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 120: Coronary Artery Calcifications
Coronary Artery Calcifications 93.9% of the cohort had LDL measured at least once Patients with total CAC Patients with total CAC score >400 20.0% (111/554) goal of <70 score >400 only 27.6% average systolic BP of last two Patients with total CAC score >400 56.7% (314/554) goal of <100 documented re
Slide 121: Quantification of Emphysema on Chest CT
Quantification of Emphysema on Chest CT • 30% Admission rate • Emphysema on CT 50% • ILA on CT 6% • Bronchiectasis on CT 6% Patients with Qualitative Emphysema on baseline CT Only 32% (315/938) were ever seen by pulmonary prior to baseline CT Patients with ILA: Only 21.2% (22/104) were ever seen by
Slide 122: Broad Screening Endorsements
Broad Screening Endorsements Risk Management • Following NLST publication and the NCCN Guidelines® many additional medical societies have recommended LDCT screening (0 before the NLST): – National Comprehensive Cancer Network (NCCN) – American Lung Association (ALA) – American Thoracic Society (ATS)
Slide 123: RESCUE LUNG RESCUE LIFE SOCIETY
123 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 124: Failure to Screen Lawsuits
Failure to Screen Lawsuits Risk Management • “…juries confronted with a plaintiff patient who develops cancer or other serious disease for which a screening test was available but not ordered by the patient’s physician, tend to find that the physician’s failure to order the test was negligent.” Berl
Slide 125: Kotter's Organizational Change
Kotter’s Organizational Change ACCC Oncology Times March/April 2014 125 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 126: Adenocarcinoma Stage IA screen example
4B: Adenocarcinoma, Grade 3/4, T1a (2cm), N0, M0 à Stage IA Screen 2007 126 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 127: CTLS Program Volume, Active Enrollment, and Cancers Diagnosed per Year
CTLS Program Volume, Active Enrollment, and Cancers Diagnosed per Year 3000 50 Interval scans Incidence scans Baseline scans Cancers diagnosed after baseline 45 Cancers diagnosed at baseline 797 Active Enrollment 2500 40 735 620 543 35 577 2000 Number of Scans/Active Number of Cancers 27 30 376 10 2
Slide 128: CT Lung Screening MD Summary
CT Lung Screening MD Summary % Qualified % Referrals % Referrals # Referrals who get who get Patients Lost to Follow Up who qualify scanned scanned MRN Status Date Discharged Average Lahey MD 20 91.5% 86.2% 78.9% 1 90 Day Letters Sent 10/11/2017 Example MD 157 84.7% 83.5% 70.7% 2 90 Day Letters Sent
Slide 129: NLCRT Quality Metrics Workgroup
https://www.lungcancerscreeningguide.org NLCRT Quality Metrics Workgroup 129 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 130: Race Breakdown in the Lung Screening Program
Race Breakdown in the Lung Screening Program Lung screening Lahey overall (FY Race program 2014) American Indian / Alaskan Native 0.09% 0.10% Asian 0.65% 3.50% Black 0.39% 1.60% Hispanic 0.30% 1.80% White 98.57% 86.20% Latin American N/A 0.20% Other / Declined N/A 6.50% 130RESCUE LUNG RESCUE LIFE SO
Slide 131: Future
Future • Act locally to change organizational culture • Remove barriers to CTLS – Rescue Lung, Rescue Life Society: Rescuing lives from lung cancer today and tomorrow • Research Opportunities – Smoking cessation, population health, and value based medicine – Molecular adjuncts – ACO environment • Ad
Slide 132: RESCUE LUNG RESCUE LIFE SOCIETY
132 RESCUE LUNG RESCUE LIFE SOCIETY
Slide 133: Saving lives at risk for lung cancer through high quality CT lung screening
RESCUE LUNG RESCUE LIFE SOCIETY Saving lives at risk for lung cancer through implementing high quality CT lung screening today and pioneering early detection innovations tomorrow. ™® WEBSITE COMING SOON | 833-RSQ-LUNG (833-777-5864) | [email protected] (-) Lahey Hospital “BR & Medical Center
Slide 134: Vision, Mission, Who We Are, Values
Vision: Rescuing Lives From Lung Cancer Today and Tomorrow Mission: Saving lives from lung cancer through implementing high quality CT lung screening today and pioneering early detection innovations tomorrow Who We Are: We are a multidisciplinary, care-giver driven, voluntary organization providing
Slide 135: Founding Board of Directors
Founding Board of Directors Officers • Kimberly Rieger Christ, PhD Research Scientist LH • Andrea McKee, MD Radiation Oncology LH • Eric Burkes, MD Pathologist BMC • Jacob Sands, MD Medical • Jennifer Lewis, MD Medical Oncology Oncology DFCI Vanderbilt • Shawn Regis, PhD • Carla Lamb, MD Interventio
Slide 136: Thanks!
Thanks! www.laheyhealth.org/lungscreening 136 RESCUE LUNG RESCUE LIFE SOCIETY
Bristol-myers Squibb Company — Investor Presentation (April 2019) on 6ix